The Global Histone Modification Patterns of Osteosarcoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Epigenetic alteration may affect a patient’s prognosis by altering the development and progression of the tumor. Some recent reports have identified a correlation between histone modification and patient outcome. However, no studies have been conducted on global histone modification in osteosarcomas. Methods: We investigated histone modification in 54 cases of osteosarcoma by performing immunohistochemical staining. The immunohistochemical expression of four histone modification markers, acetylated H4 lysine 12 (H4K12Ac), acetylated H3 lysine 18, trimethylated H3 lysine 27, and dimethylated H3 lysine 4 were evaluated. Results: High H4K12Ac expression was correlated with patient age (p=0.011). However, the other histone modification markers showed no correlation with any of the clinicopathological data such as survival, tumor grade, tumor site, metastasis, age, or gender. Conclusions: Our study showed that all four histone modification markers are expressed in osteosarcoma (median expression rate, 40 to 60%). However, we did not find a correlation with the clinicopathological factors except for age. Further study to evaluate the reason for the association between H4K12Ac and patient age is needed.
Abstract
Background: Epigenetic alteration may affect a patient’s prognosis by altering the development and progression of the tumor. Some recent reports have identified a correlation between histone modification and patient outcome. However, no studies have been conducted on global histone modification in osteosarcomas. Methods: We investigated histone modification in 54 cases of osteosarcoma by performing immunohistochemical staining. The immunohistochemical expression of four histone modification markers, acetylated H4 lysine 12 (H4K12Ac), acetylated H3 lysine 18, trimethylated H3 lysine 27, and dimethylated H3 lysine 4 were evaluated. Results: High H4K12Ac expression was correlated with patient age (p=0.011). However, the other histone modification markers showed no correlation with any of the clinicopathological data such as survival, tumor grade, tumor site, metastasis, age, or gender. Conclusions: Our study showed that all four histone modification markers are expressed in osteosarcoma (median expression rate, 40 to 60%). However, we did not find a correlation with the clinicopathological factors except for age. Further study to evaluate the reason for the association between H4K12Ac and patient age is needed.
참고문헌 (21)
- Ferrari S, "Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma", Curr Opin Oncol, 19, pp.341~346 (2007)
- Wang T, "L523S, an RNA-binding protein as a potential therapeutic target for lung cancer", Br J Cancer, 88, pp.887~894 (2003)
- Yantiss RK, "KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas", Am J Surg Pathol, 29, pp.188~195 (2005)
- Dass CR, "Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma", Clin Exp Metastasis, 22, pp.643~652 (2005)
- Foukas AF, "Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells", J Bone Joint Surg Br, 84, pp.706~711 (2002)
- Perissinotto E, "Involvement of chemokine receptor 4", stromal cell-derived factor 1 system during osteosarcoma tumor progression, 2005, pp.11(2 Pt 1), 490~497
- Wan X, "Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma", Cancer Res, 65, pp.2406~2411 (2005)
- Lund AH, "Epigenetics and cancer", Genes Dev, 18, pp.2315~2335 (2004)
- Gibbons RJ, "Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes", Hum Mol Genet, 14(Spec 1), pp.R85~R92 (2005)
- Bhalla KN, "Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies", J Clin Oncol, 23, pp.3971~3993 (2005)
- Esteller M, "The necessity of a human epigenome project", Carcinogenesis, 27, pp.1121~1125 (2006)
- Jones PA, "The fundamental role of epigenetic events in cancer", Nat Rev Genet, 3, pp.415~428 (2002)
- Esteller M, "Cancer epigenomics: DNA methylomes and histone-modification maps", Nat Rev Genet, 8, pp.286~298 (2007)
- Seligson DB, "Global histone modification patterns predict risk of prostate cancer recurrence", Nature, 435, pp.1262~1266 (2005)
- Barlési F, "Global histone modifications predict prognosis of resected non small-cell lung cancer", J Clin Oncol, 25, pp.4358~4364 (2007)
- Tzao C, "Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus", Mod Pathol, 22, pp.252~260 (2009)
- Clark JC, "A review of clinical and molecular prognostic factors in osteosarcoma", J Cancer Res Clin Oncol, 134, pp.281~297 (2008)
- Bacci G, "Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution", Cancer, 106, pp.1154~1161 (2006)
- Carsi B, "Primary osteosarcoma in adults older than 40 years", Clin Orthop Relat Res, (397), pp.53~61 (2002)
- Kawakami K, "Age-related difference of site-specific histone modifications in rat liver", Biogerontology, 10, pp.415~421 (2009)
- Peleg S, "Altered histone acetylation is associated with age-dependent memory impairment in mice", Science, 328, pp.753~756 (2010)